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Chemical analysis of multicellular tumour spheroids
L. E. Jamieson,a D. J. Harrisonb and C. J. Campbell*a
Conventional two dimensional (2D) monolayer cell culture has been considered the ‘gold standard’ tech-
nique for in vitro cellular experiments. However, the need for a model that better mimics the three dimen-
sional (3D) architecture of tissue in vivo has led to the development of Multicellular Tumour Spheroids
(MTS) as a 3D tissue culture model. To some extent MTS mimic the environment of in vivo tumours
where, for example, oxygen and nutrient gradients develop, protein expression changes and cells form a
spherical structure with regions of proliferation, senescence and necrosis. This review focuses on the
development of techniques for chemical analysis of MTS as a tool for understanding in vivo tumours and
a platform for more eﬀective drug and therapy discovery. While traditional monolayer techniques can be
translated to 3D models, these often fail to provide the desired spatial resolution and z-penetration for
live cell imaging. More recently developed techniques for overcoming these problems will be discussed
with particular reference to advances in instrument technology for achieving the increased spatial resolu-
tion and imaging depth required.
Introduction
Cell culture is used to study all aspects of cellular character-
istics and function and for in vitro testing of drug candidates
and therapies. Conventionally cells are cultured on a flat
surface in a petri dish or flask where their primary physical
contacts are with the substrate on which they are growing and
the culture medium surrounding them, with very little cell–cell
interaction.1 This suﬀers from the major drawback that the
cells are not in a realistic physiological environment. In vivo,
cells are in a 3D environment with the major physical contact
being cell–cell interactions with surrounding cells, and cell–
matrix interactions with the extracellular matrix (ECM). This
3D environment introduces complexity that is not observed in
traditional monolayer cell culture. As a result, drugs and
disease therapies that prove eﬀective in the monolayer cell
culture models often fail to carry this eﬃcacy forward into
in vivo trials.2 While tissue explants grown in culture provide a
step between monolayer cell culture and the in vivo environ-
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ment, access to such samples is limited. There is therefore a
need for an in vitro model of tumour biology that mimics
better the 3D environment that exists in vivo without the
added ethics, health, safety, cost and availability limitations
encountered when using animal models or explanted tissue.
Multicellular tumour spheroids (MTS) have become increas-
ingly used for the study of cell function and testing of drugs as
they satisfy the requirement for a more complex and physio-
logically relevant cell culture model. Attempts have been made
to incorporate cells of diﬀerent types, for example by mixing
cancer cell lines with non-malignant fibroblast or other
stromal cells.2,3 In particular MTS are used as an ex vivo model
of cancer. Importantly, the blood supply to many cancers
in vivo is poor due to rapidly proliferating cells producing cellular
masses where the centre regions may be far from the well
organised vasculature of the body. Cancer cells are capable of
signalling for the formation of new blood vessels via proteins
such as vascular endothelial growth factor (VEGF),4 however
the resulting vasculature is disorganised and leaky so does not
eﬀectively deliver oxygen and nutrients to the tumour. As a
result, concentration gradients develop in factors including
oxygen, nutrients and pH (Fig. 1).5 The concentration gradi-
ents developed in vivo are mimicked by MTS where a radial
structure develops with a core that is frequently necrotic, sur-
rounding quiescent cells and an outer proliferating layer
(Fig. 1).6
The microenvironments4 that develop in cancer give rise to
local heterogeneity in aspects including gene expression and
regulation; cell diﬀerentiation, proliferation, viability and
death; drug metabolism; and response to stimuli (Fig. 1).8
This combination of factors leads to increased complexity
when considering drug and therapy treatments in vivo com-
pared to simple monolayer cell culture assays. For example,
increased resistance to cytotoxic drugs and ionising radiation
in vivo may be a direct consequence of the microenvironment
that develops.5,9 This makes the use of MTS in drug and
therapy development increasingly important as they mimic
better the in vivo environment in comparison to traditional
monolayer culture models. This review brings together the
current techniques and enabling technologies for chemical
analysis of various characteristics of MTS. It summarises the
latest technologies being used to improve analysis of MTS as
an important model of tumour biology highlighting where
there is room for improvement in chemical, spatial and tem-
poral resolution.
Methods for growing MTS
A variety of techniques have been developed for the formation
of MTS. The basic requirement for MTS formation is that
adhesions between cells is stronger than that between cells
and the substrate they are grown on.7 The first examples of
multicellular spheroid growth were performed by Holtfreter10
who was studying gastrulation, and Moscona and Moscona11
who demonstrated the aggregation of isolated chick chondro-
genic and myogenic cells.5 These initial studies formed non-
tumour multicellular spheroids with the advantage that they
better mimic the in vivo 3D environment. While this review
focuses on MTS as an in vitro cancer tumour model, tech-
niques discussed are equally applicable to non-tumour spher-
oids and organoids.
Depending on the culture technique and cell type
employed, spheroids are formed in varying quantities, over
various time periods and with varying degrees of homogeneity
and the particular technique used is likely to be guided by the
particular application being employed. For example, using
spinner flasks allows large quantities of MTS to be formed but
these often lack homogeneity while using the hanging drop
technique allows much more homogenous and uniform MTS
formation but is diﬃcult to perform on a large scale.1,7
Fig. 2 illustrates some of the techniques employed for MTS
formation.
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Fig. 1 MTS organisation and radial changes that are established or pre-
dicted (adapted from Lin R. et al.7).
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Spontaneous aggregation
The simplest method for the formation of MTS is spontaneous
aggregation, where the cells spontaneously cluster to form cell
aggregates that grow in 3D. Technically these are cell aggre-
gates rather than MTS and only a few cell lines grow in this
way – MDA-MB-435 human breast cancer cells being one
example.1 Due to these limitations, a variety of other more
complex methods have been developed.
Hanging drop
In its simplest form, the hanging drop methods involves
growing MTS from drops of cell suspension in culture media
suspended from the lid of a petri dish (Fig. 2a). Cells aggregate
in the drops which remain in place by surface tension and
then grow into MTS.7 More recent technologies have developed
multiwell plates for the growth of MTS using the hanging drop
method including the Perfecta3D™ Hanging Drop Plates12
where the new design allows for easier treatment, media
exchange and handling of the MTS. Growing MTS using this
method allows for the formation of MTS of uniform size
although it is diﬃcult to culture large numbers of MTS in
this way.13
Gyratory methods and spinner flasks
A popular method for formation of large numbers of MTS is
the spinner flask method (Fig. 2b). This involves putting a sus-
pension of cells in media into a flask which is constantly kept
stirring. Due to the constant motion, cells are not given the
chance to adhere to surfaces in the flask and therefore aggre-
gate together and grow to form MTS. Similarly gyratory
methods involve placing the cell suspension in flasks that are
put into incubators where they are rotated by gyratory motions.
Both of these techniques allow for larger quantities of MTS to
be formed however the drawback is that the MTS formed are
heterogeneous in size and shape and the constant rotary
motion could mechanically alter the MTS.1,7
Non adhesive plates/liquid overlay
Another popular method for MTS formation involves growing
cells in plates with substrates that limit cell adhesion. This
relies on the cell–cell adhesion being stronger than the cell–
substrate adhesion, encouraging cells to aggregate and form
MTS rather than adhere to the substrate in the plate. Using
substrates such as agarose,14 polyethylene glycol (PEG) and
polydimethylsiloxane (PDMS) to coat the bottom of plates
allows for this type of MTS formation.15
Microcarrier beads
Microcarrier beads are small 100–400 µM diameter1 solid
beads on which cells are grown in 3D (Fig. 2c). They can be
produced from various materials including dextran and cellu-
lose. Microcarrier beads are available at a low cost commer-
cially and tend to allow spheroid formation from primary cells
and transformed cell lines as well as cell types which are nor-
mally diﬃcult to grow such as endothelial cells. As the beads
form the central regions of these cultures there is less likeli-
hood that a necrotic core will develop and therefore these
models are more representative of healthy cells growing in vivo
as opposed to cancer tumour cell lines.16
Scaﬀolds
Scaﬀolds are extracellular matrix (ECM) mimics that can either
be synthetic e.g. polyglycolic acid or naturally derived e.g. type
I collagen and Matrigel® (Fig. 2d). They are highly porous 3D
matrices which allow cells to attach, proliferate and diﬀeren-
tiate and guide cells to produce 3D MTS structures.2 3D Biotek
have developed culture kits based on the biodegradable
scaﬀold poly(γ-caprolactone) (PCL).17
Microwells and microfluidics
A relatively recent advancement in the growth of uniform MTS
on a large scale is the use of microwells and microfluidics,
enabled by the development of microprinting techniques
including photolithography and soft lithography.7 Arrays of
wells are printed into materials such as polyethylene glycol
(PEG), polydimethylsiloxane (PDMS) and agarose which are
nonadherent to cells.18 Thousands of wells can be printed in a
single substrate with a defined diameter. When a cell suspen-
sion is added to such a printed substrate in a plate, cells settle
into the wells such that each well contains an equal number of
cells that then form MTS homogenous in size and shape. Size
and geometry of MTS formed can be controlled by well shape
and size. Recently many systems have been developed on
microfluidic chips patterned with microwells and microchan-
nels such that MTS can be formed in arrays and, for example,
drugs can be delivered to these systems.2,15
Fig. 2 Examples of methods of MTS formation: (a) MTS being grown
using the basic hanging drop technique, (b) MTS growing in spinner
ﬂasks, (c) MTS being grown on microcarrier beads and (d) cells (red)
growing in a scaﬀold of alginate gel (green), an example of the start of
MTS growth in a scaﬀold of NovaMatrix-3D™.
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Chemical analysis of MTS –
understanding tumour physiology
A variety of techniques have been developed to investigate the
physiology of MTS and their changes in response to drugs and
therapy. These techniques include advances in instrument
technology to allow imaging in real time, in 3D; a variety of
techniques to allow observation of variation in oxygen, hypoxia,
pH and nutrients; and methods to measure protein expression
as well as general growth characteristics and morphology.
Advances in instrument technology to analyse MTS
In the simplest form standard histological methods are used
to visualise MTS but this involves fixing and sectioning the
samples, which introduces artefacts and does not allow the
observation of dynamic processes. Conventional histological
dyes also have low spatial resolution.8 New instrumentation
has allowed MTS to be analysed in situ.
Confocal microscopy can be used to view MTS with z resolu-
tion but penetration depths are limited and may not allow full
z penetration through MTS. Eﬀorts have been made to improve
resolution and penetration depth of confocal microscopy to
achieve the best images including the use of borosilicate glass
bottoms on dishes as opposed to polystyrene, a water immer-
sion microscope objective instead of a dry objective and
increased laser power/light output at deeper image depths.19
While better resolution and increased z penetration was
observed, the z penetration was still limited to 350 µM with
this technique meaning it was unable to visualise the entire
depth of a MTS.
Two and multi photon microscopy have been used for
imaging 3D samples as they can give a two to three fold
increase in penetration depth in comparison to one photon
confocal microscopy.20 Samples are probed with laser pulses
of longer wavelengths but high intensities to stimulate multi
photon excitation.21 High intensities are required to increase
the chance of non-linear multi photon excitations and the
laser is generally operated by using long wavelength femto-
second pulses of high intensity to decrease phototoxicity and
photobleaching.22 Increased z penetration and contrast are
achieved and only the point of interest is subjected to illumi-
nation so photobleaching and phototoxicity are minimised in
the surrounding sample.20–23
Recent advances in microscopy to view MTS involve the use
of optical coherence tomography (OCT) (Fig. 3b), optical pro-
jection tomography (OPT) (Fig. 3c) and light sheet microscopy
(LSM) (Fig. 3d) to map MTS. In OCT back scattered or back
reflected light is detected to provide cross sectional images
through a 3D sample.24 In OPT the sample is rotated and
straight line projections are taken through it to generate 3D
images.25,26 The advantage of OCT and OPT are that much
larger sample volumes can be imaged but resolution is much
lower than that which can be obtained from sectioned
samples viewed through standard high resolution microscopes
or by using confocal microscopy.27
A more recent and very useful microscopy advancement for
the analysis of MTS is LSM or single plane illumination
microscopy (SPIM). This involves using a light sheet, a plane
of light, to illuminate a sample as opposed to a single point.
As well as providing an image of a whole specimen slice at
once and therefore reducing acquisition time, this technique
reduces the light exposure of areas of the sample and therefore
reduces photobleaching and phototoxicity.8 It is an ideal tech-
nique for analysis of MTS as it allows whole sections through
MTS to be observed at once and z stacks to be built into a 3D
image with better z resolution than confocal microscopy
(Fig. 3d). A disadvantage of this technique is the general need
to embed samples in a transparent gel material, usually
agarose or low melting point agarose. Embedding in such
materials can impact the growth, placing mechanical restraints
on specimens and making growth time course experiments
inaccurate. Recently, Desmaison, A. et al.28 developed a sample
holder allowing MTS to be mounted in hydrogel and a time
course experiment of MTS growth to be performed.
Further advances have recently been made to LSM includ-
ing the use of self-reconstructing Bessel beams and two-
photon fluorescence excitation which saw an increase of nearly
two fold in axial resolution and 5–10 fold increase in contrast
in comparison to linear Bessel beam excitation and 3–5 fold
increase in z penetration depth in comparison to Gaussian
beam linear excitation.29,30 Very recently LSM has been per-
formed using an Airy beam to provide further advances in par-
ticular allowing a larger field of view with high contrast and
high resolution.31
Fig. 3 (a) MTS imaged using a light microscope; (b) a cross section
through the centre of an MTS using OCT; (c) an OPT image of an MTS
derived from a primary cancer specimen where blue core = implanted
MTS, green = outgrowth into culture in collagen and red = positive
immunoreactivity for Her2; and (d) LSM image of a MTS.8
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It is worth mentioning some additional microscopy tech-
niques that can reveal morphological characteristics of MTS
compared to monolayer culture. Transmission electron
microscopy (TEM) has been used to visualise cell–cell32 and
cell–ECM33 interactions in MTS while scanning electron
microscopy (SEM) reveals high magnification and high resolu-
tion information about the surface characteristics of MTS
including visualisation of cell–cell interactions and the mor-
phology of cells.34–36 Both techniques require cells to be fixed
and processed and SEM only reveals surface topology, with
samples often coated in gold removing a lot of surface detail.
Helium ion microscopy (HIM) removes the need for coating
and provides increased resolution compared to SEM.37 Fig. 4
compares morphology of monolayer cultured cells to MTS
using HIM. Table 1 summarises the microscopy techniques
used when analysing MTS along with their advantages and
limitations.
Measuring oxygen concentration and hypoxia
A significant characteristic of MTS in comparison to mono-
layer culture is variation in oxygen concentration mimicking
in vivo tumours. As tumours and MTS grow the central regions
become increasingly depleted in oxygen (and hypoxic) and
eventually cells may die creating a necrotic core.38 Hypoxia in
tumours is incredibly significant as it can induce pro-survival
signalling, leading to metabolic changes and resistance to
therapy.4,5,39,40
It is desirable to chemically analyse variations in oxygen
concentration and hypoxia through MTS. Oxygen concen-
tration and hypoxia are highly interlinked but not identical
characteristics. Oxygen concentration is singularly a measure-
ment of the level of oxygen present while hypoxia is a more
complex characteristic which can be defined in several ways
including nitroreductase activity,41 HIF activation42 and
expression of HIF associated genes43 to name a few. This dis-
tinction is important since a hypoxic phenotype (HIF stabilis-
ation, glycolytic metabolism) is a characteristic of many
cancers irrespective of oxygen concentration (Warburg
Eﬀect).44 When considering chemical analysis of MTS some
techniques have been developed specifically to measure
hypoxia as a function of, for example, nitroreductase activity,
while other techniques directly measure oxygen concentration.
One of the first methods developed for measuring hypoxia
uses small molecules such as 2-nitroimidazole that are meta-
bolised under hypoxic conditions and subsequently detected.45
An example is the commercially available Hypoxyprobe-1™
(PimonidazoleHCl)46, where the metabolised product in
hypoxic regions is detected by an antibody and subsequently
visualized by either a fluorescent tag47 or colorimetric detec-
tion (Fig. 5). This technique is limited to distinguishing cells
below and above a hypoxic limit without giving truly quantitat-
ive information. Autoradiography was used in initial detection
methods for these probes and extension to magnetic reson-
ance spectroscopy (MRS) and positron emission tomography
(PET) allowed non-invasive detection of hypoxia in living
systems.48–54 Hypoxyprobe-1™ has been used to visualise dis-
tributions of hypoxia in MTS, giving good spatial resolution,
but its use is limited to fixed sections.
Direct measurement of oxygen concentration can be
achieved using oxygen microelectrodes. These have been
miniaturised to give increased spatial resolution of oxygen
measurements both in vivo and ex vivo. The main disadvantage
is that this is an invasive technique with the risk that the
oxygen electrodes perturb their immediate environment and
thus distort values obtained.41,55
Recent advances have been made to develop increasingly
eﬃcient O2 sensing probes such as new cell-penetrating phos-
phorescent probes based on conjugates of Pt(II)-tetrakis(penta-
fluorophenyl)porphine (PtPFPP) dyes.56 The Pt probe was
conjugated with glucose which minimised aggregation and
self-quenching for measurements in aqueous media and was
used to perform high resolution phosphorescence lifetime
based O2 imaging (PLIM) in PC12 MTS. Nanoprobes have also
been used in vivo to measure reactive oxygen species (ROS)
concentrations and hypoxia and these techniques could poten-
tially be applied to MTS models and, with the use of more
advanced instrument technologies, allow live 3D imaging
through the MTS.57
pH and nutrient concentration
Lactate accumulation is common in areas of low oxygen due to
increased glycolysis, utilisation of the pentose phosphate
pathway and decreased oxidative phosphorylation.58 Therefore
decreasing oxygen concentration and hypoxia tends to corre-
late with an increase in lactate accumulation and decreasing
pH. Gradients in nutrient concentration including glucose and
Fig. 4 comparison of the morphology of cells growing in (a) monolayer
culture to (b) cells growing as MTS and (c) a magniﬁed area of cells
growing as MTS.
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ATP that are intimately linked to changes in metabolic path-
ways can also correlate with pH and oxygen gradients.
Methods for measuring pH and nutrient concentrations in
MTS are limited and primarily based on monolayer tech-
niques. Significantly, studies of pH in tumour cells have
revealed that intracellular and extracellular pH diﬀer signifi-
cantly, with intracellular pH becoming neutral to alkaline and
extracellular pH acidic.5,59 This intra- and extracellular trend is
attributed to ion pumps exporting protons from inside to
outside cells which can become activated by certain growth
factors which promote tumour angiogenesis, often associated
with requirement for increased blood supply in areas of lower
oxygen. This gradient of lower extracellular to intracellular pH
is the opposite of that observed under normal tissue con-
ditions. Detection of diﬀerences between intra- and extracellu-
lar environment requires very high resolution techniques
which are currently limited.
Most methods to detect pH in culture employ fluorescence
and can also be used in MTS, for example the intracellular
monitoring dye BCECF.60 One of the commonly used tech-
niques to monitor nutrient and pH variations in MTS is bio-
luminescence imaging. Walenta, S. et al.61 used the technique
of bioluminescence of cryosectioned non-proliferating Rat 1
aggregates and MR1 MTS to determine variations in ATP,
glucose and lactate. While bioluminescence imaging reveals
detailed information about nutrient gradients in MTS with
high spatial resolution, the resolution is not suﬃcient to dis-
tinguish intra- and extra-cellular compartments.
The more recent use of nanoprobes for pH imaging in vivo
also has potential in live MTS. This technique is based on pH
sensitive fluorescent probes conjugated to nanoprobes that
can also be antibody-targeted to specific cells. Live cell
imaging is possible but there is the drawback of limited range
of pH detection.57 Surface enhanced Raman scattering (SERS)
has been used to measure intracellular pH using gold nano-
shells functionalised with pH active molecules in monolayer
culture.62–66 This technique could be extended to MTS and has
the potential for multiplexing to allow numerous character-
istics, such as pH and redox, to be measured simultaneously.67
1H magnetic resonance chemical shift imaging of MTS
incubated with imidazole was used to provide information on
pH variations in MTS with 32 × 32 µm resolution. While this
resolution is not enough to distinguish intra- and extracellular
pH variations it revealed a 0.6 pH unit diﬀerence between
central and peripheral regions of the MTS.68
Spectroscopic imaging techniques have been used to map
changes in chemical, elemental and nutrient concentrations
in MTS. DLD-1 MTS have been analysed by scanning trans-
mission ion microscopy (STIM), proton-induced X-ray emis-
sion (PIXE) mapping, scanning X-ray fluorescence microscopy
(SXFM) and Fourier transform infrared (FT-IR). STIM revealed
useful information regarding cell density where lower density
was observed in central regions relating to the necrotic core.
PIXE revealed elemental maps giving information of element
density of P, S, Cl, K and Fe. Cu and Zn distribution were
Fig. 5 Two ﬂuorescent images of MTS stained with Hypoxyprobe-1™
(pink) where cell nuclei are stained blue.
Table 1 Summarises microscopy techniques used to visualise MTS along with advantages and limitations of each technique
Microscopy
technique Advantages Limitations
Standard Simple No z depth
Primarily fixed and sectioned samples
Confocal z Depth possible Limited to a maximum of 350 µM z depth
Two and multi-
photon
Increased z depth and contrast z Depth still limited
Photobleaching and phototoxicity to surrounding sample
minimised
OCT Can image whole MTS Resolution is poorer
OPT Can image whole MTS Resolution is poorer
LSM Can image whole MTS Samples typically embedded in a transparent gel which can
impact growthAcquisition time reduced
Photobleaching and phototoxicity reduced
TEM High resolution to visualise cell–cell and cell–ECM
interactions
Limited field of view
Involves fixing and processing samples
SEM High resolution and high magnification of surface
characteristics
Involves fixing samples
Only reveals surface information
Samples often gold coated which removes surface detail
HIM Increased resolution compared to SEM for revealing surface
characteristics
Involves fixing samples
No requirement for coating Only reveals surface information
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mapped using SXFM while FT-IR revealed detailed information
regarding the distribution of diﬀerent biomolecules such as
proteins, lipids and DNA as well as lactate.69
Proteins
Primarily as a result of the gradients of, for example, oxygen
that develop in MTS, protein expression is often altered. Stan-
dard techniques for measuring protein expression such as
Western Blotting can be diﬃcult to perform with MTS samples
due to the requirement for large numbers of cells, although
this problem has been addressed to some extent by techniques
such as in-cell westerns.2 To overcome this problem multiple
MTS for the same conditions can be used. An example study
using western blotting shows that the multidrug resistance
(MDR1) gene is hypoxia responsive and regulated by Hypoxia
Inducible Factor-1 (HIF-1).70 Both immunohistochemistry and
immunofluorescence can be used to detect and quantify
protein expression using specific antibodies. For example, pro-
teins involved in cell–cell and cell–ECM interactions and com-
ponents of ECM such as cadherins, integrins and collagens
respectively can be immunochemically stained. It is also pos-
sible to perform quantitative immunofluorescence, for example
using Automated Quantitative Analysis (AQUA), which allows
quantitation of a target signal e.g. Her2 in Fig. 6 in cells
stained for cytokeratin (tumour cells).71 While spatial infor-
mation can be acquired using these techniques there is the
need to fix samples. A similar technique that is also often used
and based on fluorescence is flow cytometry of trypsinised
samples. While this is simple and can provide quantitative
data, it removes the majority of spatial information.72,73
Bioluminescence has also been used to detect protein
expression, protein–protein interactions and enzyme activity
by employing diﬀerent versions of the luciferase bio-
luminescence assay.74,75 This is a promising technique as it
has the potential to provide spatial information by live
imaging of intact MTS. In comparison to fluorescence, bio-
luminescence has the advantage of a lower background and
therefore better sensitivity, a larger range over which quantitat-
ive signal can be obtained and less perturbation by coloured
compounds.2
Nanoprobes can be used for the detection of particular
enzymes to analyse their expression. For example, a nanoprobe
was developed to detect the activity of caspase-3, an enzyme
involved in apoptosis, where nanoparticles were conjugated
with a caspase-3 substrate and scattering colour varied as indi-
vidual nanoparticles were released by the enzyme acting to
digest the substrate.57 This technique was used in vivo but has
the potential for spatial analysis of diﬀerences in enzyme
expression in MTS.
A novel demonstration of spatially resolved protein
expression information was performed by McMahon,76 where
MTS layers were progressively trypsinised to isolate the outer
proliferating layer, middle peri-necrotic layer and necrotic
core. Mass spectrometry using an iTRAQ approach with
MALDI-TOF-TOF and ESI-Q-TOF was used to analyse the
protein content of each layer and compare and contrast. This
new approach was also complemented with traditional tech-
niques including immunohistological staining using GLUT-1
and CAIX antibodies. While this technique does not provide
highly resolved spatial information it is the first technique to
demonstrate spatial changes in protein expression through
MTS.
Another recent and promising technique based on mass
spectrometry that provides spatial information on proteins in
MTS is mass spectrometry imaging (MSI). Matrix-assisted laser
desorption/ionization mass spectrometry (MALDI) has been
used to analyse frozen or fixed tissue sections for spatial
imaging of protein and peptides as well as other species such
as lipids and small molecules.77 Typically frozen tissue sec-
tions are analysed,78 however, this technique has also been
performed on formalin-fixed, paraﬃn-embedded tissue sec-
tions.79 To limit analyte spreading during preparation, matrix-
free MSI has also been developed.80 In addition to tissue sec-
tions MALDI imaging has been performed on sectioned MTS
embedded in collagen to give information on protein vari-
ations through the structure. Proteins were identified using
MALDI-TOF-TOF and nanoflow-LC-MS/MS of lysates from MTS
and cytochrome C and histone H were both detected as two of
the species mapped. This technique is useful as it provides
spatially resolved information without the need for specific
stains such as those used in immunohistochemistry and
immunofluorescence. However it still requires samples to be
fixed or frozen and sectioned and therefore live samples
cannot be analysed.
Another emerging and promising technique for chemical
analysis of MTS is Raman imaging. This technique is a label
free and non-invasive technique for probing diﬀerences in
chemical composition. Raman imaging probes the vibrational
modes of molecules giving information on the chemical com-
position of the area being probed in a spatially resolved
Fig. 6 Quantitative immunoﬂuorescence using AQUA to quantify
target signal (Her2, red, top right) in cells marked for cytokeratin (i.e.
tumour cells, green, top left) in MTS. Nuclei are stained with DAPI (blue,
bottom right). All ﬂuorescent signals are combined in the bottom left
image.
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manner. This technique has been predominantly investigated
in monolayer culture but recently it has been shown to be
useful for the analysis of 3D MTS culture also.81 While still in
its initial stages of research, this technique is very promising
for live and label free chemical imaging of MTS.
The techniques of MSI and confocal Raman imaging (CRI)
have been combined to provide enhanced chemical infor-
mation, combining information on integrity of cells and protein
levels using CRI and small molecule location using MSI.82 In
this example, MTS were fixed, processed and sectioned for ana-
lysis. While CRI has potential for live cell imaging of whole
MTS, MSI is only possible on sectioned samples.
Localisation of and cellular response to drugs
The development of the MTS model and techniques to chemi-
cally analyse and characterise MTS has provided a more realis-
tic ex vivo model of cancer. In addition to increasing insight
into physiological characteristics of MTS, this provides a plat-
form for more eﬀective testing of drug candidates and thera-
pies.83 Screening of drug candidates on MTS gives more
reliable results saving time and money in later stages of drug
trials. Recent developments in high throughput screening have
allowed MTS to be used in place of monolayer culture, allowing
drug candidates to be better selected for eﬃcacy.13,34,84
The interesting technique of biodynamic imaging has been
used to analyse cellular response to drugs toxic to mitochon-
dria and B-Raf inhibitors.85 This is an optical technique which
monitors dynamic changes in cells over time and how these
changes vary when treated with a particular drug. Biodynamic
imaging detects dynamic light scattering using low-coherence
digital holography to elucidate information on intracellular
motions. Such motions include dynamic processes in cells
including organelle movement and cytoskeletal changes that
are often aﬀected by drug treatment. The eﬀect of drugs
aﬀecting the mitochondria and Raf kinase inhibitors on two
colon cancer cell lines was investigated using this biodynamic
imaging technique.
Nanomedicine is a rapidly advancing area of cancer
research. It is apparent that when developing promising nano-
particle based techniques for cancer therapy, imaging techno-
logies capable of successful visualising the 3D MTS structure
are essential. As already discussed the advances in instrument
technology, primarily with OCT, OPT and LSM, allows success-
ful 3D images of MTS to be formed. Fluorescent LSM would be
particularly useful for monitoring nanoparticle uptake if nano-
particles could be fluorescently labelled. Studies have investi-
gated the use of techniques such as fluorescence lifetime
imaging microscopy (FLIM) to examine the distribution of
doxorubicin (DOX) functionalised iron oxide nanoparticles
where native DOX released from the nanoparticles had a
diﬀerent fluorescence lifetime to DOX conjugated to the nano-
particles allowing distinction between released and conjugated
DOX to be investigated.86 In another study 3D multiphoton
fluorescence microscopy was successfully employed to investi-
gate the uptake of quantum dots and DOX encapsulated
in micelles.36
MALDI imaging has also been used to monitor drug uptake
in MTS. Both the drug irinotecan and its metabolites were
imaged by MALDI in HCT 116 colon cancer MTS at various
time points to investigate uptake and metabolism of the
drug.87 Raman imaging also has potential for use in drug
uptake studies in MTS.81
Conclusions
MTS are now established as a valuable in vitro tool for investi-
gation of tumour physiology and response to drugs and
therapy. There is a need for these models due to the limit-
ations of monolayer culture in displaying the complex charac-
teristics found in vivo as a result of their 2D rather than 3D
nature. This includes characteristics such as lack of cell–cell
and cell–ECM interactions and failure to develop the gradients
found in tumours where central regions become deprived of
oxygen and nutrients – a very important characteristic as
limited penetration to these areas by drugs and oxygen leads
to resistance to many therapies. However, the increasing use of
the more physiologically relevant MTS model has led to the
requirement of more sophisticated functional imaging, in real
time and in three dimensions, and chemical analysis tech-
niques to characterise the physiological environment of these
MTS and monitor responses to drugs and therapy, particularly
for use in high throughput screening methods.
The fundamental consideration when chemically analysing
MTS is choice of a suitable technique and instrumentation to
obtain the desired spatial, chemical and 3D resolution. Con-
ventional light and confocal fluorescence microscopy tech-
niques can be used to successfully image whole MTS with
limited z depth, whilst immunohistochemistry and immuno-
fluorescence can be used to image processed and sectioned
samples. Improvements to confocal microscopy along with the
use of two- and multiphoton techniques allows increasing z
penetration depth. The techniques of OCT, OPT and particu-
larly LSM have allowed whole MTS samples to be viewed and
advanced our understanding of MTS.
There is still huge potential for development in analysis of
MTS as many of the techniques currently used are based on
analysing lysed MTS which removes spatial information or
fixing and processing MTS which can introduce artefacts and
does not allow for real time imaging. Variants of traditional
techniques including flow cytometry, immunohistochemistry,
immunofluorescence, bioluminescence imaging and western
blotting are currently the main techniques employed for moni-
toring various chemical characteristics of MTS. There is con-
stant development of new techniques to allow real time
analysis of live MTS and perhaps the most promising areas for
development is in the use of nanoprobes and Raman imaging.
The combination of new probes, new imaging techniques and
improved culture techniques will help drive MTS use into the
mainstream of drug discovery. This review has highlighted
these latest areas pushing the limits of chemical analysis of
MTS and enabling technologies for imaging results. Table 2
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summarises the techniques discussed for chemical analysis
of MTS.
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